BioPartnering North America

BioPartnering North America

September 27, 2005 07:45 ET

BioPartnering North America Calls for Applications to Present 5-7 February 2006, Vancouver, B.C., Canada; Unique Opportunity for Biotech Companies to Showcase Their Technology and Products

SANTA CRUZ, CALIFORNIA--(CCNMatthews - Sept. 27, 2005) - Technology Vision Group LLC (TVG) is pleased to announce that it is accepting applications to present at the 4th Annual BioPartnering North America (BPN: www.techvision.com/bpn/) which will be held in Vancouver, B.C., Canada, on February 5-7, 2006 as a partnership between TVG, BC Biotech, BioAlberta and BIOTECanada. Applications to present can be submitted online at www.techvision.com/bpn/registration/presenter/apply.php. Like its sister conference BioPartnering Europe (BPE: www.techvision.com/bpe/) to be held in London this October, BPN provides unparalleled opportunities for innovative biotech companies from across the world to showcase their technologies and products and form business relationships. BPN 2005 was very successful and attracted 72 company presentations and 850 delegates from biotech, pharma and financial companies representing the US, Canada, Europe and Asia.

BPN 2006 will again feature all the program highlights that have contributed to its overwhelming success with Open House presentations, Emerging Company presentations, BioPartnering Leadership sessions, sponsor workshops and several networking opportunities built into everyday of the conference.

Emerging Company presentations

This year, due to high demand and popularity, the number of Emerging Company presentations has been increased to twenty. These slots are reserved for companies that were founded in or later than 2002 and offer each chosen company a 14-minute podium presentation in the main plenary hall. BPN has featured many young companies that have gone on to become the industry's most important players.

Dr. Michael Roberts, Director of Business Development at Chelsea Therapeutics commented, "We presented as part of the Emerging Company presentation series at BPN earlier this year and found it to be an extremely productive way to raise our profile to a broad range of audiences in an efficient and professional way. We will definitely return in 2006!"

Open House presentations

A trademark of BPN is the Open House presentations featuring 56 biopharmaceutical and diagnostics companies, each giving interactive presentations in specially constructed booths. Presenters are available during a two-hour period for informal discussions with business development executives, and devise unique ways to showcase aspects of their business.

Mr. Nick Woolf, Senior Vice President of Business Development for Oxford BioMedica, who will present at BPN 2006 commented, "BPN is an innovative and leading conference that attracts major North American pharma and biotechs. It's an un-missable platform for a company such as Oxford BioMedica to gain exposure to these companies, plus the potential for business development is maximised by the unique and informal environment of the Open House session."

biopartnering.com fosters B2B opportunities

Following last year's success of utilizing the newly evolving biopartnering.com online system to network for BPN, delegates will again this year be able to search partnering opportunities through keyword searches of detailed profiles on all companies, contact other delegates, arrange private meetings and reserve meeting rooms in advance of the conference. The biopartnering.com site now offers an integrated registration system, enabling registrants to easily sign-up for BPN using a single, convenient interface.

Ms. Karimah Es Sabar, Executive Director at host company BC Biotech commented, "BPN looks set to continue to be one of the most important and valuable conferences for biotech partnering in North America and we are proud to act as hosts and look forward to once again welcoming BPN's international delegates to British Columbia."

Full details about BioPartnering North America online at: www.techvision.com/bpn.

Conference Sponsors

Angiotech Pharmaceuticals, Inc., AstraZeneca, PricewaterhouseCoopers LLP, Burrill & Company, Cooley Godward LLP, Farris, Morrison & Foerster, Bristol-Myers Squibb Company, Merck, Pfizer, QLT Inc., Roche, Seed I.P. Law Group PLLC, UK Trade & Investment, Dorsey & Whitney, Genome British Columbia, Gowlings, Life Science Analytics, Inc., Quintiles Transnational Corp., UBC University-Industry Liaison Office & Sauder School of Business

Conference Supporters

Biotechnology Focus, BioWorld Today, CCNMathews, Citigate Dewe Rogerson, Contact Canada, Global Bioscience Partnership

2005 Emerging Company Presenters

Chelsea Therapeutics Inc., Chimerix, Inc., CovX, Cryptome Pharmaceuticals Limited, enGene, Inc., GlyTag LLC, ImaRX Therapeutics, Prolexys Pharmaceuticals, Inc., Protox Therapeutics, QRS Phenotyping Inc., Quintessence Biosciences, Inc., Santhera Pharmaceuticals AG, Synexa Life Sciences, T-cellic A/S, VIRIONICS CORPORATION, Zymeworks

2005 Open House Presenters

Active Pass Pharmaceuticals, Affitech AS/Affitech USA, Inc., Allon Therapeutics, Alphora Research Inc., AnorMED Inc., Antisoma, Aradigm Corporation, atugen AG, AVI BioPharma, Inc., Avidex, BioImage A/S, Biolex, Inc., Biopta Ltd., BioVex Limited, BioVisioN AG, BioWa, Inc., Cardiome Pharma Corp., Cobra BioManufacturing Plc, Corgentech, Cytokinectics, Inc., Debiopharm SA, Delta Biotechnology Limited, Enobia Pharma (BioMep), EvoGenix, Evolutec Group Plc, Evotec OAI, Forbes Medi-Tech Inc., Inex Pharmaceuticals Corporation, Inflazyme Pharmaceuticals, Ingenium Pharmaceuticals AG, Inimex Pharmaceuticals, Inc., InNexus Biotechnology Inc., Inpharmatica, JERINI, Light Sciences Corporation, Medicago Inc., Meristem Therapeutics, MorphoSys AG, National Research Council Institute for Marine Biosciences, Nautilus Biotech, OncoGenex Technologies Inc., OptiNose AS, Oxford BioMedica, Patheon Inc., REPLICor, Resverlogix, Santhera Pharmaceuticals AG, Scottish Biomedical, SemBioSys Genetics, Inc., Torcan Chemical Ltd., ToxTest, Transition Therapeutics Inc., Twinstrand Therapeutics Inc., Valeo Management L.P., Xantos Biomedicine AG, YM BioSciences Inc.

Contact Information